Press Releases

 
Press Releases
Date Title and Summary View
Feb 7, 2014 MADISON, Wis. (February 07, 2014) – Novelos Therapeutics, Inc. (OTCQX: NVLT) a pharmaceutical company developing novel agents for the treatment and diagnosis of cancer, is pleased to announce that it has closed the previously disclosed non-brokered private placement of two-year, 8% convertible debentures and warrants, raising...
PDF
Feb 6, 2014 Proceeds Enable Initiation of Phase II Trial of 124I-CLR1404 in Glioma in First Quarter 2014 MADISON, Wis. (February 06, 2014) – Novelos Therapeutics, Inc. (OTCQX: NVLT) a pharmaceutical company developing novel agents for the treatment and diagnosis of cancer, today announced it has entered into definitive ag...
PDF
Nov 13, 2013 Board Appoints Paul Berns as New Independent Director and Reduces Board from Nine to Five Directors Company to Relocate Executive Offices, Close Newton Office and Centralize Operations in Madison, Wisconsin Company Initiates Key Management Changes to Support New Strategic Initiatives and Transition of Operations to Madison...
PDF
Oct 9, 2013 MADISON, Wisc. (October 9, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT) announced that the Board of Directors, on October 4, 2013, appointed Dr. Simon Pedder as Acting Chief Executive Officer and elected him a Director, replacing Harry Palmin, to complete a previously announced leadership transition. ...
PDF
Jul 29, 2013 MADISON, Wisc. (July 29, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry Palmin, the company’s President and CEO and a Director, will step down from his positions with the company, in order to pur...
PDF
May 16, 2013 To Begin I-124-CLR1404 (LIGHT) Phase 2 Imaging Trial in Brain Cancer in Early 2014 Evaluating I-131-CLR1404 (HOT) Potential Phase 2 Indications and Trial Designs To File CLR1502 (GLOW2) IND for Intraoperative Tumor Margin Illumination by End 2013 ...
PDF
Feb 21, 2013 MADISON, Wisc. (February 21, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the closing of a public offering of 11,000,000 units at $0.50 per unit for gross proceeds of $5,500,000. Each unit consisted of one shar...
PDF
Feb 13, 2013 MADISON, Wisc. (February 13, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the pricing of a public offering of 11,000,000 units at $0.50 per unit for gross proceeds of $5,500,000. Each unit consists of one share...
PDF
Feb 4, 2013 MADISON, Wisc. (February 4, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present a corporate update at the 15th Annual BIO CEO & Investor Conference ...
PDF
Jan 31, 2013 Oral Presentation Highlights Cancer-Targeted PET Imaging, Therapeutic and Optical Imaging Compounds that Offer Broad-Spectrum Diagnosis and Treatment of Solid Tumors MADISON, Wisc. (January 31, 2013) – Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs ...
PDF
Page: FirstPrevious ...
16
NextLast